Back to Search
MARK LEVIS, M.D.
M.D.
Medical Oncology Physician
NPI: 1578507976Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
D52391(MD)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D52391(MD)
Education
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO SCHOOL OF MEDICINE
Class of 1994
Research & Publications (20)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
PMID 16857987·Blood·2006
8-other
FLT3 and acute myeloid leukemia: what is the wild type receptor up to?
PMID 16330422·Haematologica·2005
8-other
Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia.
PMID 15604892·Curr Opin Hematol·2005
6-review
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
PMID 15126317·Blood·2004
7-preclinical
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
PMID 12010785·Blood·2002
7-preclinical
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
PMID 11468194·Blood·2001
8-other
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
PMID 19654408·Blood·2009
7-preclinical
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
PMID 19109557·Blood·2009
3-trial
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
PMID 19029442·Blood·2009
3-trial
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
PMID 18955566·Blood·2009
7-preclinical
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
PMID 18483374·Clin Cancer Res·2008
3-trial
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.
PMID 18452067·Leuk Lymphoma·2008
6-review
Images in clinical medicine. FLT3 Mutation and acute myelogenous leukemia with leukostasis.
PMID 17942876·N Engl J Med·2007
5-case
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
PMID 17851558·Leukemia·2007
7-preclinical
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells.
PMID 17686054·Br J Haematol·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1578507976
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile